PRS4243
Anti-IFN-β antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-Interferon, beta 1, fibroblast
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human, mouse
technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... IFNB1(3456)
General description
Interferon-β (IFN-β) is a cytokine that belongs to type I interferons. The IFN-β gene is mapped on the human chromosome at 9p21.3.
Immunogen
a 17 amino acid peptide from near the center of human IFN-b.
Biochem/physiol Actions
Interferon-β (IFN-β) plays a major role in antibacterial and antiviral defense. It is also involved in apoptosis, cell growth, and autoimmune disorders. It binds to multimeric cell receptors and successful binding results in a cascade of intracellular events.
Physical form
Solution in phosphate buffered saline containing 0.02% sodium azide
Other Notes
The action of this antibody can be blocked using blocking peptide SBP4243.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Stephen Cunningham et al.
Clinical pharmacology and therapeutics, 78(6), 635-646 (2005-12-13)
Interferon IFN-beta is indicated for the treatment of multiple sclerosis. A significant proportion of patients show a poor clinical response to therapy. Type I interferon exerts its effect at least partially through interaction of specific transcription factors with interferon-stimulated response
Dongdong Xu et al.
Bioactive materials, 35, 82-98 (2024-01-29)
Repetitive implant-related infections (IRIs) are devastating complications in orthopedic surgery, threatening implant survival and even the life of the host. Biofilms conceal bacterial-associated antigens (BAAs) and result in a "cold tumor"-like immune silent microenvironment, allowing the persistence of IRIs. To
Amber Kaplan et al.
Journal of immunology (Baltimore, Md. : 1950), 198(10), 4036-4045 (2017-04-16)
Type I IFNs are a cytokine family essential for antiviral defense. More recently, type I IFNs were shown to be important during bacterial infections. In this article, we show that, in addition to known cytokine functions, IFN-β is antimicrobial. Parts
L Runkel et al.
Pharmaceutical research, 15(4), 641-649 (1998-05-20)
Two recombinant IFN-beta products have been approved for the treatment of multiple sclerosis, a glycosylated form with the predicted natural amino acid sequence (IFN-beta-1a) and a non-glycosylated form that has a Met-1 deletion and a Cys-17 to Ser mutation (IFN-beta-1b).
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service